Mercy BioAnalytics

Private

Commercial-stage biotechnology company in Natick, Massachusetts, developing blood-based early cancer detection tests built on its Mercy Halo platform, which analyses tumour-derived extracellular vesicles to detect stage I cancers such as ovarian and lung cancer.

Company Info

Sector:Diagnostics

Headquarters:Natick, Massachusetts, USA

Founded:2018

Website:mercybio.com/

Funding Round:Series B

Total Funding:~$100M

Upcoming Milestones & Key Dates

2027

Clinical

Evident ovarian cancer screening pivotal study

Clinical Development Pipeline

Mercy Halo Ovarian

Target: Tumour-derived extracellular vesicles

Ovarian cancer screening (stage I detection)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Mercy Halo Lung

Target: Tumour-derived extracellular vesicles

Lung cancer detection

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Leadership Team

Dawn Mattoon, PhD

Chief Executive Officer

Toumy Guettouche, PhD

Chief Scientific Officer

Ellen Snow

Chief Financial Officer

Careers & Job Openings

See all open roles

All departments

Multiple locations